Form 4: Verrica COO Buys $42K in Stock, Warrants

Verrica Pharmaceuticals' Chief Operating Officer, David Zawitz, purchased 10,000 shares of common stock and associated warrants, signaling confidence in the company's future.

Summary

• David Zawitz, Chief Operating Officer of Verrica Pharmaceuticals Inc. (VRCA), acquired 10,000 shares of common stock and 2,500 Series C Warrants.
• The transaction occurred on November 25, 2025.
• The purchase was made through 10,000 investment units, each consisting of one share of common stock and a Series C warrant for one-fourth of a share of common stock.
• The price per investment unit was $4.2425, totaling $42,425.
• Following this transaction, Mr. Zawitz directly beneficially owns 21,000 shares of common stock and 2,500 Series C Warrants.
• The Series C Warrants have an exercise price of $6.315 per share and expire on November 25, 2030.
• The reported share numbers reflect a 1-for-10 reverse stock split effective July 24, 2025.
• The transaction was made pursuant to a Rule 10b5-1(c) plan.

Sentiment

Score: 8

Explanation: The significant purchase of common stock and warrants by a high-ranking executive like the COO is a strong positive signal, indicating management's confidence in the company's future. This insider buying, especially after a reverse stock split, suggests a belief in the company's turnaround or upcoming positive developments.

Positives

• A key executive, the Chief Operating Officer, is increasing his direct ownership in the company, signaling strong confidence in its future prospects.
• The purchase of both common stock and warrants indicates a belief in both current value and potential future appreciation.
• The transaction was executed under a Rule 10b5-1(c) plan, suggesting a pre-planned investment strategy.

Risks

• The filing itself does not detail specific company risks, as it is a transaction report. However, the existence of warrants and a reverse stock split could imply past financial challenges or efforts to manage share price.

Future Outlook

The filing does not contain explicit forward-looking statements or guidance, but the insider purchase suggests management's positive outlook on future company performance.

Industry Context

Insider buying, particularly by a Chief Operating Officer, can be interpreted as a positive signal within the biotechnology and pharmaceutical industry, indicating management's belief in upcoming product milestones, clinical trial success, or market potential, especially following a reverse stock split which can sometimes be viewed negatively.

Related Party Transactions

• The transaction involves a company officer (David Zawitz) purchasing securities from the issuer (Verrica Pharmaceuticals Inc.), which is a related party transaction.

Stakeholder Impact

• Shareholders: Existing shareholders may view this insider purchase as a positive signal, potentially increasing confidence and demand for the stock.
• Employees: May see this as a sign of stability and future growth, potentially boosting morale.
• Creditors: Could interpret this as a positive indicator of the company's financial health and future prospects, potentially reducing perceived credit risk.

Key Dates

Recommendation

The Chief Operating Officer's substantial investment in company stock and warrants, particularly following a reverse stock split, is a strong vote of confidence. This insider buying suggests management believes the stock is undervalued and anticipates positive future developments, making it an attractive 'buy' signal for investors.

Keywords

Verrica Pharmaceuticals, VRCA, Insider Trading, Stock Purchase, Warrants, David Zawitz, Chief Operating Officer, SEC Form 4, Biotechnology, Pharmaceuticals